Trial Profile
Prophylactic Treatment For Chemo-induced Neutropenia. Use Of G-csf Biosimilar (Nivestim(Registered)) According To The Chemotherapy Context: Adjuvant Versus Metastatic
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- Acronyms VISTA
- Sponsors Hospira; Pfizer
- 16 Jun 2017 Status changed from recruiting to completed.
- 27 Jul 2015 Secondary endpoints been amended.
- 29 May 2015 New trial record